Biosect,
I've seen others say we need a facility here in the U.S. by law when it comes to biological based products, I'm certainly no expert but I believe the FDA will want to see the facility duplicated here. I believe that CRL can meet that demand, but don't know if they're in the process of doing it, or waiting approval in the U.K. and perhaps a formal announcement of their relationship with NWBO to be released.
I believe CRL has multiple facilities that can be adapted to DCVax-L production with the addition of a number of the FlaskWorks units. The facilities already contain all else that is needed to support the production of the vaccine.
Probably the most important thing that people like Dr. Liau need to communicate to their colleagues is that any brain cancer patient they're operating on should have their tumors properly preserved. If they can get that message across, on approval the demand for DCVax-L could be huge as there would be a backlog of patients who potentially could benefit from its use. I really can't say what percentage of the current brain surgeons know of DCVax-L or how tumors should be preserved to make it. I believe the leukapheresis can be done just prior to making the vaccine, if I'm wrong about that, please let me know.
It's my belief that worldwide there are many facilities that could easily add a number of FlaskWorks units and could rapidly become a DCVax-L production unit. Many of these facilities may already be owned by CRL, but unless they're somehow limited, I believe the company could line up many other similar facilities to create regional distribution facilities if that was what they wished to do. I feel certain that either UCLA or City of Hope could perform such a function for all of Southern California if that was desired, and I believe there are others here that could do it as well.
Gary
Market Data 
Markets 
AI
